Assessment of Giant Cell Arteritis Medical Practices in France

Key facts

Sponsor

Chugai Pharma France

Principal Investigator

Alfred MAHR, Professor

alfred.mahr@aphp.fr

Enrollment

306 enrolled

Eligibility

50 years · All sexes

Timeline

2018 – 2018

Study locations (1)

• Hospital of the Archet, Nice, Alpes-Maritimes, France

Collaborators

ITEC Services

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Giant cell arteritis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07108387
  Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
  National Institute of Allergy and Infectious Diseases (NIAID)
• RECRUITINGNCT07246577
  The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant Cell Arteritis.
  Vastra Gotaland Region
• RECRUITINGNCT07206238
  Orbital Vascular Inflammation in Ischemic Optic Neuropathy and Giant Cell Arteritis
  Rigshospitalet, Denmark
• RECRUITINGNCT07084480
  Giant Cell Arteritis - Ways to Precision Medicine
  Wuerzburg University Hospital
• RECRUITINGNANCT07001059
  oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound
  Hôpital NOVO
• RECRUITINGNCT06894602
  Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis
  University Hospital, Brest
• RECRUITINGNCT05749094
  Optic Nerve Sheath Ultrasound in Giant Cell Arteritis
  Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
• ACTIVE NOT RECRUITINGNCT05703763
  The Applanation Tonometry in GCA Pilot
  Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

See all trials for Giant cell arteritis →